InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: None

Saturday, 05/07/2011 6:02:39 PM

Saturday, May 07, 2011 6:02:39 PM

Post# of 80490
Rida selected "Best Of ASCO"

Each year, an ASCO committee selects the abstracts that represent the "foremost research in oncology today." These abstracts are then highlighted for presentation and discussion at the Best of ASCO Meetings.

Check out the 1:45 PM – 2:30 PM time slot:
http://boa2011.asco.org/BestofASCOSEATTLE/MeetingProgram/ProgramAgenda.aspx

Sarcoma
William Tap, MD - University of Calfornia, Los Angeles
Abstract #10005: Results of the phase 3, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (Sant P. Chawla, MD)

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.